Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93

類似資料

• Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
  著者:: Pagani, Olivia, 等
  出版事項: (2008)
• Adjuvant!(©) Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer
  著者:: Paridaens, Robert J., 等
  出版事項: (2010)
• Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V
  著者:: Colleoni, Marco, 等
  出版事項: (2016)
• Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century
  著者:: Pagani, Olivia, 等
  出版事項: (2009)
• Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer
  著者:: Gruber, G., 等
  出版事項: (2008)